| |
Tumor/non-tumor tissues pairs (n = 11)
|
Tumor tissues (n = 12)
|
ctDNA (n = 22)
|
|---|
|
Sex, n (%)
|
|
Men
|
5 (45%)
|
6 (50%)
|
16 (73%)
|
|
Women
|
6 (55%)
|
6 (50%)
|
6 (27%)
|
|
Age in years, mean (min-max)
|
| |
60 (44–79)
|
75 (55–84)
|
63 (36–82)
|
|
Location of the tumor, n (%)
|
|
Duodenum
|
/
|
1 (8%)
|
/
|
|
Cecum
|
2 (18%)
|
2 (17%)
|
2 (9%)
|
|
Right colon
|
2 (18%)
|
6 (50%)
|
3 (13%)
|
|
Transverse colon
|
/
|
2 (17%)
|
1 (5%)
|
|
Left colon
|
5 (46%)
|
/
|
11 (50%)
|
|
Rectosigmoid junction
|
1 (9%)
|
1 (8%)
|
1 (5%)
|
|
Rectum
|
1 (9%)
|
/
|
4 (18%)
|
|
Conservation, n (%)
|
|
FFPE
|
8 (72%)
|
12 (100%)
|
/
|
|
Freezing
|
3 (28%)
|
/
|
/
|
|
Histology, n (%)
|
|
ADC
|
11 (100%)
|
12 (100%)
|
19 (86%)
|
|
Tubular adenoma
|
/
|
/
|
1 (5%)
|
|
NA
|
/
|
/
|
2 (9%)
|
|
Stage, n (%)
|
|
I
|
1 (9%)
|
2 (17%)
|
2 (9%)
|
|
II
|
4 (37%)
|
5 (42%)
|
/
|
|
III
|
3 (27%)
|
2 (17%)
|
/
|
|
IV
|
3 (27%)
|
2 (17%)
|
20 (91%)
|
|
ND
|
/
|
1 (8%)
|
/
|
|
Microsatellite stability, n (%)
|
|
MSS
|
7 (64%)
|
2 (17%)
|
16 (72%)
|
|
MSI
|
3 (27%)
|
10 (83%)
|
1 (5%)
|
|
NA
|
1 (9%)
|
/
|
5 (23%)
|
|
Mutational status, n (%)
|
|
KRAS mutation
|
3 (27%)
|
3 (25%)
|
7 (32%)
|
|
NRAS mutation
|
/
|
/
|
2 (9%)
|
|
BRAF mutation
|
3 (27%)
|
4 (33%)
|
1 (5%)
|
|
Other mutations
|
/
|
/
|
1 (5%)
|
|
No mutation
|
1 (9%)
|
5 (42%)
|
11 (50%)
|
|
NA
|
4 (36%)
|
/
|
/
|
|
MLH1 methylation, n (%)
|
|
Presence (≥ 5%)
|
3 (27%)
|
9 (75%)
|
/
|
|
Absence (< 5%)
|
/
|
3 (25%)
|
/
|
|
NA
|
8 (73%)
|
/
|
22 (100%)
|
- ADC adenocarcinoma, ctDNA circulating tumor DNA, FFPE formalin-fixed paraffin-embedded, MSS microsatellite stable, MSI microsatellite instability, NA not available
